Wikipedia -WSS

Wikipedia

author：leisure time 2025-10-01 00:52:21 - browse：7

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Eli Lilly expects to double planned employment in Boston center

WSS

Redefining sustainability for the pharmaceutical industry

'Vaccine

Will Ozempic

Hospital price transparency does save money, advocate argues

FDA gives detailed accounting of AI

Are embryos people? Reproductive medicine's future depends on the answer

focus

Wikipedia

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Pharmacists can make shortage drugs, but at what cost?

Walensky prepares to leave CDC — and Congress — behind

Pharmacists can make shortage drugs, but at what cost?

Cancer drug shortages should be causing more outrage

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Medicare proposal to cover medical devices draws a mixed reaction

CDC advisory group OKs chikungunya vaccine

Cancer drug shortages should be causing more outrage

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

focus

Cholera vaccine supplies dangerously low, outbreaks surging

Laying a path for careers in science

Ohio train derailment: Experts on toxic chemical risks

FDA struggles to regulate food additives, sometimes for decades

FDA struggles to regulate food additives, sometimes for decades

Redefining sustainability for the pharmaceutical industry

explore

focus

entertainment

focus